Stock screener

AVTX

Conviction 96HealthcareScan · Thu, Jun 25, 2026
AVTX$18.00-0.88%
ResistanceSupportVol 14Insider sell
63 bars
16
Vol MA14 2.29M
Mar 26Apr 14May 1May 19Jun 8Jun 25
Avalo Therapeutics, Inc.PHARMACEUTICAL PREPARATIONSwww.avalotx.com
Price18.00
Change-0.88%
Gap-0.06%
Rel volume5.09×
Avg volume2.06M
Avg $ vol32M
SMA 2014.98
SMA 5015.76
SMA 20015.70
Price vs 50+14.22%
Price vs 200+14.66%
MA stackbullish
50/200 crossgolden · 1d
Supertrendup · 14.72
RSI (14)64
MACD hist0.55
MACD crossbull · 6d
Stoch %K / %D89 / 90
ADX (14)22
+DI / −DI32 / 15
RSI divergence
MACD divergence
ATR %+6.75%
ADR %7.13%
52w high22.87
52w low4.75
From 52w high-21.29%
Above 52w low+278.95%
New 52w highNo
SqueezeOff
Bollinger width45.52%
%B0.94
Donchian pos89.11%
Donchian high18.67
Donchian low12.52
AVWAP (52w high)17.06
vs AVWAP high+5.54%
AVWAP (52w low)16.23
vs AVWAP low+10.91%
OBV trendDown
Chaikin MF (20)-0.31
Today vs 20d5.09×
Avg vol (14d)2.29M
Avg vol (20d)2.06M
Avg $ vol (20d)32M
Market cap946.18M
RS 3m (vs SPY)+22.76%
RS 6m (vs SPY)-10.10%
RS line new highNo
Trend template7/8
Technical rank69.3
1 week+16.88%
1 month+12.36%
3 months+29.03%
6 months-6.10%
1 year+263.64%
YTD+5.76%
P/E-12.09
P/B13.85
P/S
P/FCF-18.35
EPS-5.84
Div yield
ROE-114.55%
ROA-78.35%
Debt/Eq0.22
Current7.66
EV/EBITDA-12.90
Gross margin
Net margin
Rev growth-86.62%
EPS growth-122.78%
Price target45.90
Target upside155.00%
Analyst ratingBuy
Institutional61.75%
Ent. value936.5M
Revenue0
Net income-19.63M
Gross profit
Free cash flow-51.55M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out52.57M
Employees33
ListedFri, Nov 13, 2015
Free float21.22M
Float %86.6%
Short interest6.38M
Days to cover4.4d
Short volume69.3%
Squeeze score96 / 100
Next earningsThu, Aug 6, 2026 (42d)
EPS forecast−$0.66 · 6 est
Last EPS vs est−$0.98 vs −$1.00
Last surprise+2.0% beat
Setup gradeA+
Conviction96 / 100
Pattern quality
Tech rank69.3 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance20.34
Support13.90
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in AVTX

All disclosures →
No recent disclosed trades by Congress in AVTX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in AVTX · 4 buys · 6 sells

InsiderSideShares
Doyle Mittie
Chief Medical Officer · Common Stock · 2026-06-23
Sell1.45K
Doyle Mittie
Chief Medical Officer · Common Stock · 2026-06-23
Exercise1.45K
Doyle Mittie
Chief Medical Officer · Stock Option (Right to Buy) · 2026-06-23
Exercise1.45K
Philip Ron M
Director · Stock Option (Right to Buy) · 2026-06-23
Grant40.2K
VARKI PAUL
Chief Legal Officer · Common Stock · 2026-06-10
Tax1.08K
Sullivan Christopher Ryan
Chief Financial Officer · Common Stock · 2026-06-10
Tax138
Doyle Mittie
Chief Medical Officer · Common Stock · 2026-06-10
Tax1.08K
Riley Jennifer
Chief Strategy Officer · Common Stock · 2026-06-10
Tax588
Jain Rita
Director · Stock Option (Right to Buy) · 2026-06-02
Grant20.1K
KANTOFF AARON
Director · Stock Option (Right to Buy) · 2026-06-02
Grant20.1K

SEC filings

EDGAR filings in AVTX · 7 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.